Heron Therapeutics stock analysis
Heron Therapeutics (0J4V) Share Price & Analysis
0J4V Stock Chart & Stats
- Day’s Range
- $0.27 - $0.29
- 52-Week Range
- $0.26 - $1.57
- Previous Close
- $0.30
- Volume
- N/A
- Average Volume (3M)
- 131.41K
- Market Cap
- $53.70M
- Enterprise Value
- $169.18M
- Total Cash (Recent Filing)
- $23.45M
- Total Debt (Recent Filing)
- $131.73M
- Price to Earnings (P/E)
- ―
- Beta
- 1.75
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- -0.03
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
APONVIE Adoption And Share Gains
Rapid APONVIE sales, account growth, procedure coverage and share gains indicate expanding adoption in the surgical market. Continued penetration can diversify Heron’s commercial base and support a more durable acute-care growth engine beyond its established products.
High Gross Margin And Improving Operating Leverage
A gross margin near 70% provides meaningful contribution potential as product volumes grow, while improved adjusted EBITDA shows operating leverage is emerging. If maintained, this combination can narrow losses and strengthen the economics of Heron’s commercial portfolio.
Strategic Asset Sale Supports Liquidity
The asset sale creates a significant source of cash and additional contingent value, with proceeds designated to repay Heron’s working capital facility. Completing the transaction could reduce financing pressure while preserving potential participation in future ZYNRELEF economics.
Bears Say
Extreme Leverage And Fragile Capital Structure
Very high leverage leaves little equity protection against operating setbacks and limits financial flexibility. Debt service, refinancing and covenant demands can absorb resources that would otherwise fund commercialization, making the business more vulnerable during product or legal disruption.
CINVANTI Faces Generic-entry Risk
Potential generic competition threatens the durability of CINVANTI’s revenue and market position, especially because it is Heron’s largest product. Even with an appeal and defensive strategy, uncertain timing and pricing pressure could weaken cash generation and portfolio scale.
Persistent Losses And Negative Cash Generation
Moderating cash burn is encouraging, but continued negative operating and free cash flow means Heron is not yet self-funding. Ongoing losses increase reliance on asset monetization, financing or spending reductions and may constrain investment in sales expansion and growth initiatives.
Heron Therapeutics News
0J4V FAQ
What was Heron Therapeutics’s price range in the past 12 months?
What is Heron Therapeutics’s market cap?
When is Heron Therapeutics’s upcoming earnings report date?
How were Heron Therapeutics’s earnings last quarter?
Is Heron Therapeutics overvalued?
Does Heron Therapeutics pay dividends?
What is Heron Therapeutics’s EPS estimate?
How many shares outstanding does Heron Therapeutics have?
What happened to Heron Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Heron Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Heron Therapeutics Stock Smart Score
Company Description
Heron Therapeutics
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Craig Alexander Collard
- Employees
- 128
- Website
- www.herontx.com
- Address
- 25 Fenton Main Street, Cary, NC, 27511, US
Heron Therapeutics (0J4V) Earnings & Revenues
0J4V Earnings Call
Earnings Call SentimentNegative
The call showed meaningful commercial strengths — notably strong year-over-year growth in the acute care franchise, particularly APONVIE and ZYNRELEF, improved adjusted EBITDA, and proactive balance sheet and legal actions. However, the June court decision creating potential generic competition for CINVANTI (the company's largest product), the subsequent withdrawal of full-year guidance, reduced pro forma cash after required principal payments, an increased GAAP net loss, and a pause in sales force expansion introduce significant near-term uncertainty. Overall, positive operating pockets are overshadowed by material legal, cash and guidance risks.
View all GB:0J4V earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |












